Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.
Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
In a 6 week pilot study, 20 individuals with habitual sleep restriction will all be asked to
extend their nightly sleep by 1 hour, and will then be randomized 1:1 to nightly
controlled-release oral melatonin (2mg) or placebo. The investigators will assess whether
sleep extension and nightly melatonin supplementation in the community is a feasible
intervention with a beneficial effect on the following chronic kidney disease (CKD) risk
factors: systemic and renal specific renin-aldosterone-angiotensin system (RAAS) activation
(systemic plasma renin activity, plasma angiotensin II levels, 24-hour urine aldosterone
excretion, and renal plasma flow response to captopril); nocturnal blood pressure measured by
24-hour ambulatory blood pressure monitor; central blood pressure measured by pulse wave
analysis; and glucose metabolism measured by Minimal Model assessment of insulin resistance
and β-cell response to a mixed meal protocol.